{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T18:20:58Z","timestamp":1771870858276,"version":"3.50.1"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.cct.2020.106154","type":"journal-article","created":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T20:42:16Z","timestamp":1600548136000},"page":"106154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Data monitoring committees for clinical trials evaluating treatments of COVID-19"],"prefix":"10.1016","volume":"98","author":[{"given":"Tobias","family":"M\u00fctze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Friede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2020.106154_bb0005","author":"World Health Organization (WHO)"},{"issue":"10223","key":"10.1016\/j.cct.2020.106154_bb0010","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"issue":"10223","key":"10.1016\/j.cct.2020.106154_bb0015","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.cct.2020.106154_bb0020","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2020.106154_bb0025","author":"World Health Organization (WHO)"},{"key":"10.1016\/j.cct.2020.106154_bb0030","author":"Center for Systems Science and Engineering (CSSE)"},{"issue":"5","key":"10.1016\/j.cct.2020.106154_bb0035","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.cct.2020.106154_bb0045","article-title":"Remdesivir for the treatment of Covid-19 \u2014 preliminary report","volume":"22","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2020.106154_bb0050","article-title":"Remdesivir for 5 or 10 days in patients with severe Covid-19","volume":"27","author":"Goldman","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.cct.2020.106154_bb0055","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1001\/jama.2020.8115","article-title":"Randomized clinical trials and COVID-19","volume":"323","author":"Bauchner","year":"2020","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.cct.2020.106154_bb0060","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJMe1712330","article-title":"We can do better \u2014 Improving outcomes in the midst of an emergency","volume":"377","author":"Baden","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2020.106154_bb0065","first-page":"1","article-title":"Dexamethasone in hospitalized patients with Covid-19 - Preliminary report","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2020.106154_bb0070","author":"U.S. Food and Drug Administration (FDA)"},{"key":"10.1016\/j.cct.2020.106154_bb0075","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/1744666X.2020.1792778","article-title":"Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19","volume":"16","author":"Sattui","year":"2020","journal-title":"Expert. Rev. Clin. Immunol."},{"issue":"4","key":"10.1016\/j.cct.2020.106154_bb0080","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/1740774517707743","article-title":"Recommendations for data monitoring committees from the clinical trials transformation initiative","volume":"14","author":"Calis","year":"2017","journal-title":"Clin. Trials"},{"issue":"4","key":"10.1016\/j.cct.2020.106154_bb0085","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/1740774518764855","article-title":"Data monitoring committees: current issues","volume":"15","author":"Fleming","year":"2018","journal-title":"Clin. Trials"},{"issue":"22","key":"10.1016\/j.cct.2020.106154_bb0090","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2016.16070","article-title":"Enhancing the scientific integrity and safety of clinical trials","volume":"316","author":"Lewis","year":"2016","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.cct.2020.106154_bb0095","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1056\/NEJMra1510066","article-title":"Data monitoring committees \u2014 Expect the unexpected","volume":"375","author":"DeMets","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cct.2020.106154_bb0100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/1740774516688915","article-title":"Data monitoring committees: promoting best practices to address emerging challenges","volume":"14","author":"Fleming","year":"2017","journal-title":"Clin. Trials: J. Soc. Clin. Trials"},{"key":"10.1016\/j.cct.2020.106154_bb0105","series-title":"Data Monitoring Committees in Clinical Trials: A Practical Perspective","author":"Ellenberg","year":"2002"},{"key":"10.1016\/j.cct.2020.106154_bb0110","author":"U.S. Food and Drug Administration (FDA)"},{"key":"10.1016\/j.cct.2020.106154_bb0115","author":"Committee for Medicinal Products for Human Use (CHMP)"},{"key":"10.1016\/j.cct.2020.106154_bb0120","author":"UNICEF\/UNDP\/WorldBank\/WHO"},{"issue":"3","key":"10.1016\/j.cct.2020.106154_bb0125","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/sim.4780060325","article-title":"Methods for combining randomized clinical trials: strengths and limitations","volume":"6","author":"Demets","year":"1987","journal-title":"Stat. Med."},{"issue":"4","key":"10.1016\/j.cct.2020.106154_bb0130","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/1740774518764449","article-title":"How to construct an optimal interim report: what the data monitoring committee does and doesn't need to know","volume":"15","author":"Neaton","year":"2018","journal-title":"Clin. Trials"},{"issue":"4","key":"10.1016\/j.cct.2020.106154_bb0135","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/2168479017739268","article-title":"Reports to independent data monitoring committees","volume":"52","author":"Buhr","year":"2018","journal-title":"Therap. Innov. Regul. Sci."},{"key":"10.1016\/j.cct.2020.106154_bb0140","author":"World Health Organization"},{"key":"10.1016\/j.cct.2020.106154_bb0145","first-page":"1","article-title":"Efficient adaptive designs for clinical trials of interventions for COVID-19","author":"Stallard","year":"2020","journal-title":"Statistics Biopharm. Res."},{"issue":"4","key":"10.1016\/j.cct.2020.106154_bb0150","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ejhf.761","article-title":"Independent academic data monitoring committees for clinical trials in cardiovascular and cardiometabolic diseases","volume":"19","author":"Filippatos","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"4","key":"10.1016\/j.cct.2020.106154_bb0155","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/216847900604000410","article-title":"Confidentiality and trial integrity issues for adaptive designs","volume":"40","author":"Gallo","year":"2006","journal-title":"Drug Inform. J."},{"issue":"2","key":"10.1016\/j.cct.2020.106154_bb0160","doi-asserted-by":"crossref","first-page":"119","DOI":"10.7326\/M19-1491","article-title":"Presenting risks and benefits: helping the data monitoring committee do its job","volume":"172","author":"Evans","year":"2020","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.cct.2020.106154_bb0165","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/pst.1912","article-title":"How can we make better graphs? An initiative to increase the graphical expertise and productivity of quantitative scientists","volume":"18","author":"Vandemeulebroecke","year":"2019","journal-title":"Pharm. Stat."},{"issue":"10","key":"10.1016\/j.cct.2020.106154_bb0170","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/psp4.12455","article-title":"Effective visual communication for the quantitative scientist","volume":"8","author":"Vandemeulebroecke","year":"2019","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"4","key":"10.1016\/j.cct.2020.106154_bb0175","first-page":"1","article-title":"Clinical trial drug safety assessment with interactive visual analytics","volume":"1","author":"Wang","year":"2020","journal-title":"Statistics Biopharm. Res."},{"key":"10.1016\/j.cct.2020.106154_bb0180","author":"UW\u2013Madison SDAC"},{"key":"10.1016\/j.cct.2020.106154_bb0185","author":"UW-Madison SDAC"},{"key":"10.1016\/j.cct.2020.106154_bb0190","author":"Rho Inc"},{"issue":"6","key":"10.1016\/j.cct.2020.106154_bb0195","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1177\/2168479018754846","article-title":"The safety explorer suite","volume":"52","author":"Wildfire","year":"2018","journal-title":"Therap. Innov. Regul. Sci."},{"key":"10.1016\/j.cct.2020.106154_bb0200","author":"Rho Inc"},{"key":"10.1016\/j.cct.2020.106154_bb0205","author":"Wildfire"},{"issue":"42","key":"10.1016\/j.cct.2020.106154_bb0210","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1093\/eurheartj\/ehu131","article-title":"Competing risks analyses: objectives and approaches","volume":"35","author":"Wolbers","year":"2014","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.cct.2020.106154_bb0215","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risk and multi-state models","volume":"26","author":"Putter","year":"2007","journal-title":"Stat. Med."},{"issue":"6","key":"10.1016\/j.cct.2020.106154_bb0220","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.cct.2020.106154_bb0225","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/pst.1915","article-title":"On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies","volume":"18","author":"Unkel","year":"2019","journal-title":"Pharm. Stat."},{"issue":"6","key":"10.1016\/j.cct.2020.106154_bb0230","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/1740774506073467","article-title":"Current controversies in data monitoring for clinical trials","volume":"3","author":"Pocock","year":"2006","journal-title":"Clin. Trials"},{"issue":"2","key":"10.1016\/j.cct.2020.106154_bb0235","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc. Ser. B Methodol."},{"key":"10.1016\/j.cct.2020.106154_bb0240","series-title":"Group Sequential Methods with Applications to Clinical Trials","author":"Turnbull","year":"1999"},{"issue":"1","key":"10.1016\/j.cct.2020.106154_bb0245","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/19466315.2015.1117017","article-title":"Statistical monitoring of safety in clinical trials","volume":"8","author":"Zhu","year":"2016","journal-title":"Statistics Biopharm. Res."},{"issue":"2","key":"10.1016\/j.cct.2020.106154_bb0250","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/biomet\/64.2.191","article-title":"Group sequential methods in the design and analysis of clinical trials","volume":"64","author":"Pocock","year":"1977","journal-title":"Biometrika"},{"key":"10.1016\/j.cct.2020.106154_bb0255","author":"Anderson"},{"issue":"2","key":"10.1016\/j.cct.2020.106154_bb0260","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/biomet\/70.2.315","article-title":"Sequential analysis of the proportional hazards model","volume":"70","author":"Sellke","year":"1983","journal-title":"Biometrika"},{"issue":"2","key":"10.1016\/j.cct.2020.106154_bb0265","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2307\/2531021","article-title":"Sample-size formula for the proportional-hazards regression model","volume":"39","author":"Schoenfeld","year":"1983","journal-title":"Biometrics"},{"issue":"12","key":"10.1016\/j.cct.2020.106154_bb0270","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/(SICI)1097-0258(19960630)15:12<1285::AID-SIM309>3.0.CO;2-0","article-title":"The role of external evidence in data monitoring of a clinical trial","volume":"15","author":"Pocock","year":"1996","journal-title":"Stat. Med."},{"key":"10.1016\/j.cct.2020.106154_bb0275","author":"U.S. Food and Drug Administration (FDA)"},{"issue":"1","key":"10.1016\/j.cct.2020.106154_bb0280","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2288-8-34","article-title":"Simpson's paradox visualized: the example of the rosiglitazone meta-analysis","volume":"8","author":"R\u00fccker","year":"2008","journal-title":"BMC Med. Res. Methodol."},{"issue":"1","key":"10.1016\/j.cct.2020.106154_bb0285","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pst.397","article-title":"Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies","volume":"10","author":"Chuang-Stein","year":"2011","journal-title":"Pharm. Stat."},{"issue":"2","key":"10.1016\/j.cct.2020.106154_bb0290","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/009286150003400218","article-title":"Pooling in integrated safety databases","volume":"34","author":"McEntegart","year":"2000","journal-title":"Drug Inform. J."},{"issue":"1","key":"10.1016\/j.cct.2020.106154_bb0295","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1740774512465495","article-title":"Meta-analysis of clinical trial safety data in a drug development program: answers to frequently asked questions","volume":"10","author":"Berlin","year":"2013","journal-title":"Clin. Trials: J. Soc. Clin. Trials"},{"key":"10.1016\/j.cct.2020.106154_bb0300","article-title":"Methods for evidence synthesis in the case of very few studies","volume":"6","author":"Bender","year":"2018","journal-title":"Res. Synth. Methods"},{"issue":"1","key":"10.1016\/j.cct.2020.106154_bb0305","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/jrsm.1217","article-title":"Meta-analysis of few small studies in orphan diseases","volume":"8","author":"Friede","year":"2017","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.cct.2020.106154_bb0310","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v093.i06","article-title":"Bayesian random-effects meta-analysis using the bayesmeta R package","volume":"93","author":"R\u00f6ver","year":"2020","journal-title":"J. Stat. Softw."},{"issue":"1","key":"10.1016\/j.cct.2020.106154_bb0315","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jrsm.1370","article-title":"Random-effects meta-analysis of few studies involving rare events","volume":"11","author":"G\u00fcnhan","year":"2020","journal-title":"Res. Synth. Methods"},{"issue":"1","key":"10.1016\/j.cct.2020.106154_bb0320","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/0962280219833079","article-title":"Dynamically borrowing strength from another study through shrinkage estimation","volume":"29","author":"R\u00f6ver","year":"2020","journal-title":"Stat. Methods Med. Res."},{"issue":"4","key":"10.1016\/j.cct.2020.106154_bb0325","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/biom.12242","article-title":"Robust meta-analytic-predictive priors in clinical trials with historical control information","volume":"70","author":"Schmidli","year":"2014","journal-title":"Biometrics"},{"issue":"4","key":"10.1016\/j.cct.2020.106154_bb0330","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/cpt.1723","article-title":"Beyond randomized clinical trials: use of external controls","volume":"107","author":"Schmidli","year":"2020","journal-title":"Clin. Pharmacol. Therapeutics"},{"key":"10.1016\/j.cct.2020.106154_bb0335","author":"Weber"},{"issue":"1","key":"10.1016\/j.cct.2020.106154_bb0340","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/1352458510382129","article-title":"A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis","volume":"17","author":"Chataway","year":"2011","journal-title":"Mult. Scler. J."},{"issue":"5","key":"10.1016\/j.cct.2020.106154_bb0345","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/bimj.201900020","article-title":"Adaptive seamless clinical trials using early outcomes for treatment or subgroup selection: methods, simulation model and their implementation in R","volume":"62","author":"Friede","year":"2020","journal-title":"Biom. J."},{"issue":"5","key":"10.1016\/j.cct.2020.106154_bb0350","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.csda.2010.10.027","article-title":"An R package for implementing simulations for seamless phase II\/III clinical trials using early outcomes for treatment selection","volume":"56","author":"Parsons","year":"2012","journal-title":"Comput. Statistics Data Anal."},{"issue":"5","key":"10.1016\/j.cct.2020.106154_bb0355","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/bimj.200710453","article-title":"A comparison of methods for adaptive treatment selection","volume":"50","author":"Friede","year":"2008","journal-title":"Biom. J."},{"issue":"4","key":"10.1016\/j.cct.2020.106154_bb0360","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/bimj.200510232","article-title":"Confirmatory seamless phase II\/III clinical trials with hypotheses selection at interim: general concepts","volume":"48","author":"Bretz","year":"2006","journal-title":"Biom. J."},{"key":"10.1016\/j.cct.2020.106154_bb0365","doi-asserted-by":"crossref","DOI":"10.1177\/1740774520941419","article-title":"Non-adjustment for multiple testing in multi-arm trials of distinct treatments: rationale and justification","author":"Parker","year":"2020","journal-title":"Clin. Trials"},{"key":"10.1016\/j.cct.2020.106154_bb0370","doi-asserted-by":"crossref","DOI":"10.1177\/1740774520941420","article-title":"Commentary on Parker and Weir","author":"Bretz","year":"2020","journal-title":"Clin. Trials"},{"key":"10.1016\/j.cct.2020.106154_bb0375","article-title":"Avoiding the termination of ACTT","volume":"31","author":"Epstein","year":"2020","journal-title":"Eur. Heart J."},{"issue":"22","key":"10.1016\/j.cct.2020.106154_bb0380","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/eurheartj\/ehaa461","article-title":"Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an expert consensus position paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"41","author":"Anker","year":"2020","journal-title":"Eur. Heart J."},{"issue":"7","key":"10.1016\/j.cct.2020.106154_bb0385","first-page":"1","article-title":"Clinical trials impacted by the COVID-19 pandemic: adaptive designs to the rescue?","volume":"22","author":"Kunz","year":"2020","journal-title":"Statistics Biopharm. Res."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714420302329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714420302329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:52:58Z","timestamp":1761555178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714420302329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":76,"alternative-id":["S1551714420302329"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2020.106154","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Data monitoring committees for clinical trials evaluating treatments of COVID-19","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2020.106154","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106154"}}